Amicus Therapeutics, Inc. (FOLD) Receives “Outperform” Rating from Robert W. Baird
Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “outperform” rating reiterated by research analysts at Robert W. Baird in a research report issued on Wednesday. They currently have a $18.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $16.00. Robert W. Baird’s target price would suggest a potential upside of 10.84% from the stock’s previous close.
Several other research analysts have also recently issued reports on the stock. Leerink Swann reissued an “outperform” rating and set a $17.00 price target (down from $18.00) on shares of Amicus Therapeutics in a report on Saturday, September 16th. BidaskClub downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 2nd. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Cowen and Company reaffirmed a “buy” rating and issued a $16.00 price objective (up previously from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $16.50 price objective (down previously from $17.50) on shares of Amicus Therapeutics in a report on Wednesday, September 13th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Amicus Therapeutics has a consensus rating of “Buy” and a consensus price target of $17.92.
Shares of Amicus Therapeutics (NASDAQ:FOLD) traded up 9.21% on Wednesday, hitting $16.24. The stock had a trading volume of 10,582,440 shares. The company’s market cap is $2.67 billion. Amicus Therapeutics has a one year low of $4.41 and a one year high of $16.60. The firm’s 50-day moving average is $13.82 and its 200-day moving average is $10.45.
Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. The company had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same quarter last year, the business earned ($0.40) EPS. On average, analysts expect that Amicus Therapeutics will post ($1.31) EPS for the current fiscal year.
In related news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The shares were purchased at an average price of $12.25 per share, with a total value of $18,375,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 3.40% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC boosted its position in Amicus Therapeutics by 3.4% during the second quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock worth $215,876,000 after purchasing an additional 705,153 shares in the last quarter. Redmile Group LLC grew its holdings in Amicus Therapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after purchasing an additional 668,080 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Amicus Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after buying an additional 430,486 shares in the last quarter. Palo Alto Investors LLC increased its position in shares of Amicus Therapeutics by 0.7% in the second quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after buying an additional 57,800 shares in the last quarter. Finally, Janus Capital Management LLC increased its position in shares of Amicus Therapeutics by 3.6% in the first quarter. Janus Capital Management LLC now owns 7,136,697 shares of the biopharmaceutical company’s stock valued at $50,883,000 after buying an additional 244,906 shares in the last quarter.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.